Cristina Elena Mitrofan Aurelia Cretu Costica Mitrofan Camelia Bar Cristina Mihaela Ghiciuc


Amiodarone, a primarily class III antiarrhythmic drug is one of the most commonly used drug in atrial fibrillation. A possible rare side effect of amiodarone treatment is to develop a diffuse parenchymal lung disorder - amiodarone pulmonary toxicity (APT). There is no pathognomonic finding to diagnose APT. A 64-year-old patient with multiple comorbidities presented in our hospital with worsening a five-month history of grade 3 mMRC dyspnea, wheezing, frequent nonproductive cough, fatigue. She has a medical history of atrial fibrillation in treatment with amiodarone 400mg/day for 2 years. Her oxygen saturation was 90% on room air, chest radiography showed disseminated lung irregular opacities with a tendency to confluence in right and left lung and chest computed tomography scan showed asymmetric centrilobular nodules and asymmetrical areas of dense ground glass opacity with few consolidation. Amiodarone pulmonary toxicity was suspected, the drug was stopped and treatment with methylprednisolone started. Worsening and progression of the disease can still be noted despite stopping amiodarone because of the long persistence and elimination of the drug, with the tendency to concentrate in tissues, such as lung. In our patient case the evolution and prognosis were good even the case illustrates neglected effects of amiodarone, potential severe one.



amiodarone, pulmonary drug toxicity, computed tomography scan, amiodarone complications

1. Camus P, Foucher P, Bonniaud P, Ask K. Drug-induced infiltrative lung disease. Eur Respir J. 2001; 18:93-100.
2. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013; 51(4): 260-277. doi: 10.1016/j.resinv.2013.09.001.
3. Florek JB, Girzadas D. Amiodarone. Book shelf . National Library of Medicine 2021. [ available at 11.07.2022 ]
4. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009; 16(2): 43–48. doi: 10.1155/2009/282540.
5. Mahavadi P, Knudsen L, Venkatesan S, et al. Regulation of macroautophagy in amiodarone induced pulmonary fibrosis. J Pathol. 2015; 1(4): 252–263. doi: 10.1002/cjp2.20
6. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009; 2(2): 103–121. doi: 10.1038/mi.2008.85.
7. Al-Shammari B, Khalifa M, Bakheet SA, Yasser M. A Mechanistic Study on the Amiodarone-Induced Pulmonary Toxicity. Oxid Med Cell Longev. 2016; 2016: 6265853. doi: 10.1155/2016/6265853.
8. Bui A, Han S, Alexandre M, et al. Pulmonary function testing for the early detection of drug-induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity. Intern Med J. 2020; 50(11): 1311-1325. doi: 10.1111/imj.14647.
9. Bégaud B, Evreux JC, Jouglard J, Lagier G. Unexpected or toxic drug reaction assessment (imputation). Actualization of the method used in France. Therapie. 1985; 40: 111-118.
10. Arimone Y, Bidault I, Dutertre JP, et al. Réactualisation de la méthode française dimputabilité des effets indésirables des medicaments. Therapie. 2011; 66 (6): 517–525. doi:10.2515/THERAPIE/2011073.
How to Cite
Mitrofan, C. E., Cretu, A., Mitrofan, C., Bar, C., & Ghiciuc, C. M. (2022). Amiodarone induced lung disease. Archive of Clinical Cases, 9(3), Arch Clin Cases. 2022; 9(3):126-132.
Case Reports

How to Cite

Mitrofan, C. E., Cretu, A., Mitrofan, C., Bar, C., & Ghiciuc, C. M. (2022). Amiodarone induced lung disease. Archive of Clinical Cases, 9(3), Arch Clin Cases. 2022; 9(3):126-132.